Detail of the clinical trial
| Title of the trial | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11) |
|---|---|
| EudraCT number | 2019-003152-37 |
| Protocol number | MK3475-A18/ENGOT-cx11 |
| Sponsor | Merck Sharp & Dohme LLC, 126 East Lincoln Ave.,P.O.BOX 2000,Rahway, New Jersey 07065, United States of America |
| Indications | Oncology |
| Diagnosis | Cervical Cancer |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2020 |
| Date of approval by Institute (SÚKL) | 6.4.2020 |
| Date of approval by EC | |
| Date of initiation CT in ČR | 5.8.2020 |
| Date of ending CT in ČR | |
| Notice | |
| Sites |
FN Královské Vinohrady, Radioterapeutická a onkologická klinika, Praha 10 Fakultní nemocnice Brno,Gynekologicko-porodnická klinika,Obilní trh 11,Brno,625 00 Krajská zdravotní, a.s., Masarykova nemocnice v Ústí n/Labem, o.z.,Onkologické oddělení,Sociální péče 3316/12A,Ústí nad Labem,400 11 (discontinued) Fakultní nemocnice Olomouc,Onkologická klinika ,I. P. Pavlova 6,Olomouc,779 00 Fakultní nemocnice v Ostrava,Klinika onkologická,17. listopadu 1790/5,Ostrava-Poruba ,708 52 |
cz